Relief Therapeutics Holding SA and NeuroX Group SA have signed a binding term sheet for a proposed business combination that aims to revolutionize the field of AI-based therapeutics. This collaboration will merge Relief’s expertise in innovative treatments for rare diseases with NeuroX’s cutting-edge digital neurotherapeutics and brain health technologies.
The resulting platform will offer a comprehensive suite of clinical interventions and pharmacological treatments to enhance the quality of life for patients, caregivers, and families. With NeuroX’s validated portfolio and strong pharmaceutical partnerships, this partnership marks a significant milestone in the journey towards expanding the reach of breakthrough therapies. Stay tuned for more updates on this exciting development in the biopharmaceutical industry.
Read more from finance.yahoo.com